| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 129.72M | 111.34M | 85.89M | 71.75M | 50.61M | 30.32M |
| Gross Profit | 41.91M | 35.81M | 29.26M | 23.16M | 17.70M | 11.19M |
| EBITDA | 31.87M | 27.96M | 25.78M | 20.02M | 14.46M | 8.97M |
| Net Income | 18.56M | 16.38M | 17.24M | 12.87M | 10.14M | 4.79M |
Balance Sheet | ||||||
| Total Assets | 170.17M | 175.89M | 154.40M | 128.66M | 107.17M | 87.00M |
| Cash, Cash Equivalents and Short-Term Investments | 2.84M | 7.53M | 18.13M | 20.43M | 31.80M | 17.50M |
| Total Debt | 14.15M | 4.90M | 5.36M | 5.14M | 5.25M | 5.29M |
| Total Liabilities | 50.06M | 43.78M | 34.84M | 32.74M | 21.13M | 16.31M |
| Stockholders Equity | 120.12M | 132.11M | 119.56M | 95.92M | 86.04M | 70.69M |
Cash Flow | ||||||
| Free Cash Flow | 29.78M | 28.76M | 16.67M | 15.40M | 14.23M | 12.12M |
| Operating Cash Flow | 29.86M | 28.84M | 16.79M | 15.73M | 14.33M | 12.15M |
| Investing Cash Flow | -26.08M | -21.11M | -14.82M | -18.53M | -3.24M | -1.46M |
| Financing Cash Flow | -23.26M | -18.58M | -4.06M | -8.85M | 3.11M | 3.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £412.39M | 21.86 | 15.29% | 2.13% | 32.67% | -1.61% | |
71 Outperform | £512.80M | 15.68 | 27.48% | 3.65% | 5.78% | -6.80% | |
70 Outperform | £264.19M | 22.92 | 10.14% | 3.78% | 3.22% | -71.97% | |
69 Neutral | £872.52M | 59.60 | 3.76% | 1.19% | 9.25% | -51.82% | |
66 Neutral | £212.55M | 34.29 | 6.18% | 1.83% | 23.37% | 4.75% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
53 Neutral | £84.85M | -5.73 | -11.22% | 12.88% | -14.31% | -361.93% |
Elixirr International plc has disclosed that Amanda Ferguson, the wife of co-founder and board adviser Ian Ferguson, sold 2,998 ordinary shares in the company on 8 January 2026 at 834p per share. Following the transaction, Ian Ferguson remains beneficially interested in 2,237,385 shares, representing about 4.51% of Elixirr’s issued share capital, indicating that despite the family’s partial disposal, his stake and alignment with shareholders remain significant.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £866.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.